The Impact of Glucagon-like Peptide-1 Receptor Agonists on Obese Individuals’ Quality of Life and Eating Behaviors

Aya S Aldewachi 1, Mohammed Ibrahim Aladul 1 *
More Detail
1 Department of Clinical Pharmacy, College of Pharmacy, University of Mosul, Ninevah, Iraq
* Corresponding Author
J CLIN MED KAZ, Volume 22, Issue 6, pp. 60-72. https://doi.org/10.23950/jcmk/17366
OPEN ACCESS 341 Views 49 Downloads
Download Full Text (PDF)
Author Contributions: Conceptualization, M.I.A.; methodology, A.S.A. and M. I.A.; validation, M.I.A.; formal analysis, A.S.A. and M. I.A.; investigation, A.S.A. and M. I.A.; resources, A.S.A. and M. I.A.; data curation, A.S.A. and M. I.A.; writing – original draft preparation, A.S.A. and M. I.A.; writing – review and editing, M. I.A.; visualization, A.S.A. and M. I.A.;  supervision, M. I. A.; project administration, M. I.A.; funding acquisition, not applicable. All authors have read and agreed to the published version of the manuscript

Data availability statement: The corresponding author can provide the data supporting the study's conclusions upon request. Due to ethical and privacy constraints, the data are not publicly accessible.

Artificial Intelligence (AI) Disclosure Statement: AI-Unassisted Work.

ABSTRACT

Background: Obesity is a multifactorial, neurobehavioral, chronic disease associated with long-term metabolic and psychosocial health consequences, all of which affect the quality of life (QoL). Eating behavior is an essential and critical factor that is connected to both the development of obesity and its effect on QoL. While glucagon-like peptide-1 receptor agonists (GLP-1RAs) show promise for improving both weight and metabolic parameters, their effects on specific eating behaviors, particularly emotional eating, remain incompletely understood.
Objectives: This study aims to investigate the complex relationships between obesity, eating behaviors, and QoL in individuals with different BMI categories.
Methods: This cross-sectional study utilized both online and face-to-face surveys conducted among a cohort of Iraqi individuals with BMI higher than 18.5 which were users and non-users of GLP-1RAs between December 2024 and March 2025.
Results: Participants with higher BMI demonstrated higher scores of emotional overeating (EOE) and hunger, while satiety responsiveness and slowness in eating were inversely related. Hunger scores were lower in GLP-1RAs users with higher QoL scores, though EOE remained elevated. Behavioral clustering demonstrated that the fuzzy eaters’ group are associated with high EOE, and low satiety, while the gourmets’ group are associated with higher food enjoyment and slower eating.
Conclusion: Despite improving appetite regulation and QoL, GLP-1RAs do not completely address emotional eating. Behavioral clustering provides an insight to understand individual differences in obesity-related behavior and necessitates the need for personalized interventions. Physiologic and psychological dimensions of obesity must both be dealt with for the improvement of patient well-being.
Keywords: Obesity, eating behavior, quality of life, semaglutide, liraglutide

CITATION

Aldewachi AS, Aladul MI. The Impact of Glucagon-like Peptide-1 Receptor Agonists on Obese Individuals’ Quality of Life and Eating Behaviors. J CLIN MED KAZ. 2025;22(6):60-72. https://doi.org/10.23950/jcmk/17366

REFERENCES

  • Bray GA, Frühbeck G, Ryan DH, Wilding JPH. Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. Obes Rev. 2017; 18 (7): 715–723. https://doi.org/10.1111/obr.12551.
  • World Health Organization. Obesity and overweight. World Health Organization. 2024. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight .
  • Global Nutrition Report. Country Nutrition Profiles. Global Nutrition Report. 2025. https://globalnutritionreport.org/resources/nutrition-profiles/asia/western-asia/iraq/.
  • Al-Shammaa ZM, Aladul MI, Essa NS. Assessment of appetitive traits among Iraqi population. Clin Epidemiol Glob Health. 2025; 33: 102014. https://doi.org/10.1016/j.cegh.2025.102014.
  • Webber J. The comorbidities of obesity. Pract Diabetes Int. 2001; 18 (8): 293–296. https://doi.org/10.1002/pdi.274.
  • Katz DA, McHorney CA, Atkinson RL. Impact of obesity on health-related quality of life in patients with chronic illness. J Gen Intern Med. 2000; 15 (11): 789–796. https://doi.org/10.1046/j.1525-1497.2000.90906.x.
  • van Strien T, Frijters JER, Bergers GPA, Defares PB. The Dutch Eating Behavior Questionnaire (DEBQ) for assessment of restrained, emotional, and external eating behavior. Int J Eat Disord. 1986; 5 (2): 295–315. https://doi.org/10.1002/eat.20424.
  • Boutelle KN, Manzano MA, Eichen DM. Appetitive traits as targets for weight loss: The role of food cue responsiveness and satiety responsiveness. Physiol Behav. 2020; 224: 113018. https://doi.org/10.1016/j.physbeh.2020.113018.
  • Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MBD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021; 384 (11): 989–1002. https://doi.org/10.1016/j.physbeh.2020.113018.
  • Furlan GB, de Souza RJ, Mancini MC, Halpern B. Use of GLP-1 analogs in the treatment of obesity: an integrative and systematic review. Int J Nutrology. 2023; 16 (1). https://doi.org/10.54448/ijn23105.
  • Charlotte C. van Ruiten, Jennifer S. ten Kulve, Liselotte van Bloemendaal, Max Nieuwdorp, Dick J. Veltman, Richard G. IJzermanvan. Eating behavior modulates the sensitivity to the central effects of GLP-1 receptor agonist treatment: a secondary analysis of a randomized trial. Psychoneuroendocrinology. 2022; 137: 105667. https://doi.org/10.1016/j.psyneuen.2022.105667.
  • Alruwaitaa MA, Alenezi A, Almutairi A, Almutairi A, Alotaibi A, Alharbi A, Aljaser A, Aljaser F, Alzahrani A, Alzahrani F, Alzahrani M, Alzahrani N, Alzahrani R, Alzahrani S, Alzaid A. The Arabic Version of the Adult Eating Behavior Questionnaire among Saudi Population: Translation and Validation. Nutrients. 2022; 14 (21): 4705. https://doi.org/10.3390/nu14214705.
  • Ziegler O, Scheen A, Nouwen A, Rigalleau F, Pichelin M, Poulain JP, Hanachi M, Fournier G, Roche F, Drouin P, Lantieri O, Taillard J, Philip P. Development and validation of a French obesity-specific quality of life questionnaire: Quality of Life, Obesity and Dietetics (QOLOD) rating scale. Diabetes Metab. 2005; 31(3 Pt 1): 273–283. https://doi.org/10.1016/s1262-3636(07)70194-5.
  • Blundell JE, Finlayson G, Axelsen M, Flint A, Gibbons C, Kvist T, Lawton C, Martins C, Moller EC, Nordgren TM, Pedersen SD, Radionov A, Raben A, Sorensen LB, Westerterp-Plantenga MS, Winkler J, Zhang Y, Chan PS. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab. 2017; 19 (9): 1242–1251. https://doi.org/10.1111/dom.12932.
  • Davies MJ, Bergenstal R, Bode B, Kushner RF, Lewin A, Skjøth TV, Harney K, Koenen C, Bain SC. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial. JAMA. 2015; 314 (7): 687–699. https://doi.org/10.1001/jama.2015.9676.
  • Suzuki T, Ito C, Kato Y, Kusunoki Y, Kawai K, Murai M, Seino Y, Inagaki N. Tirzepatide ameliorates eating behaviors regardless of prior exposure to glucagon-like peptide receptor agonists in Japanese patients with type 2 diabetes mellitus. J Diabetes Complications. 2024; 38 (7): 108779. https://doi.org/10.1016/j.jdiacomp.2024.108779.
  • van Strien T, van Beers I, van Kruistum C, Hakko E, Herman CP, Anschutz D. Emotional eating and food intake after sadness and joy. Appetite. 2013; 66: 20–25. https://doi.org/10.1016/j.appet.2013.02.016.
  • Shaw K, O'Rourke P, Del Mar C, Kenardy J. Psychological interventions for overweight or obesity. Cochrane Database Syst Rev. 2005 Apr 18;(2):CD003818. https://doi.org/10.1002/14651858.CD003818.pub2.
  • Konuksever D, Kaya AK, Çelik N, Öztürk A, Karakaş Ç, Karakuş E, Yılmaz S, Öztürk Y. The association between insulin resistance, sleep disorders, and inflammation in obese children. J Clin Med Kaz. 2023;20(3):82–87. https://doi.org/10.23950/jcmk/13327.
  • Wardle J, Haase AM, Steptoe A, Nillapun M, Jonwutiwes K, Bellisle F. Gender differences in food choice: the contribution of health beliefs and dieting. Ann Behav Med. 2004; 27 (2): 107–116. https://doi.org/10.1207/s15324796abm2702_5.
  • Raspopow K, Matheson K, Abizaid A, Anisman H. Unsupportive social interactions influence emotional eating behaviors. The role of coping styles as mediators. Appetite. 2013 Mar;62:143-9. https://doi.org/10.1016/j.appet.2012.11.031.
  • Herman CP, Polivy J. External cues in the control of food intake in humans: the sensory-normative distinction. Physiol Behav. 2008 Aug 6;94(5):722-8. https://doi.org/10.1016/j.physbeh.2008.04.014.